Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 18/20 | 0.75 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.48 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.48 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6159487 | 0.91 | MAPK14 (0.76) | MAPK14FGFR1FGFR2FGFR3 | |
| SCHEMBL6159146 | 0.88 | MAPK14 (0.81) | MAPK14FGFR1FGFR2FGFR3 | |
| SCHEMBL1417101 | 0.86 | MAPK14 (1.00) | MAPK14 | |
| SCHEMBL27460660 | 0.85 | MAPK14 (0.79) | MAPK14FGFR1FGFR2FGFR3 | |
| SCHEMBL6159836 | 0.83 | MAPK14 (0.57) | MAPK14FGFR1FGFR2FGFR3 | |
| SCHEMBL27581393 | 0.82 | MAPK14 (0.75) | MAPK14FGFR1FGFR2FGFR3 | |
| SCHEMBL6160416 | 0.81 | MAPK14 (0.70) | MAPK14FGFR1FGFR2FGFR3 | |
| SCHEMBL6160656 | 0.79 | MAPK14 (0.69) | MAPK14FGFR1FGFR2FGFR3 | |
| SCHEMBL6160359 | 0.78 | MAPK14 (0.68) | MAPK14FGFR1FGFR2FGFR3 | |
| SCHEMBL6160881 | 0.77 | MAPK14 (0.69) | MAPK14FGFR1FGFR2FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6979693-B2 | Pyrazole derivatives-p38 MAP kinase inhibitors | SYNTEX (U.S.A.) LLC (US) | 2005-12-27 | — | — | US | disclosed |
| EP-1075467-B1 | PYRAZOLE DERIVATIVES AS P-38 MAP KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2005-03-30 | — | — | EP | disclosed |
| CN-1147476-C | Pyrazole derivatives as P-38 MAP kinase inhibitors | - | 2004-04-28 | — | — | CN | disclosed |
| US-20030018051-A1 | Pyrazole derivatives - p38 MAP kinase inhibitors | GOLDSTEIN DAVID MICHAEL (US) | 2003-01-23 | — | — | US | disclosed |
| US-20020156114-A1 | Pyrazole derivatives - p38 MAP kinase inhibitors | GOLDSTEIN DAVID MICHAEL (US) | 2002-10-24 | — | — | US | disclosed |
| CN-1376147-A | Pyrazole derivatives | HOFFMANN LA ROCHE (CH) | 2002-10-23 | — | — | CN | disclosed |
| US-6444696-B1 | 1-ARYL OR HETEROARYL SUBSTITUTED 5-AMINO-4 CARBONYLPYRAZOLE DERIVATIVES; ANTIINFLAMMATORY AGENTS | SYNTEX (U.S.A.) LLC | 2002-09-03 | — | — | US | disclosed |
| US-20020103245-A1 | Pyrazole derivatives P38 MAP kinase inhibitors | GOLDSTEIN DAVID MICHAEL (US) | 2002-08-01 | — | — | US | disclosed |
| US-6376527-B1 | ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASES | SYNTEX (U.S.A.) LLC | 2002-04-23 | — | — | US | disclosed |
| US-6316466-B1 | Pyrazole derivatives P-38 MAP kinase inhibitors | SYNTEX (U.S.A.) LLC | 2001-11-13 | — | — | US | disclosed |
| CN-1300282-A | Pyrazole derivatives as P-38 MAP kinase inhibitors | HOFFMANN LA ROCHE (CH) | 2001-06-20 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018051-A1 | Pyrazole derivatives - p38 MAP kinase inhibitors | MAPK1, MAPK8, MAP3K8 | MAPK14 32/4885FGFR1 1317/4885FGFR2 2815/4885 |
| US-20020103245-A1 | Pyrazole derivatives P38 MAP kinase inhibitors | MAPK1, MAPK8, MAPKAPK2 | MAPK14 34/4885FGFR1 1656/4885FGFR2 3098/4885 |
| US-20020156114-A1 | Pyrazole derivatives - p38 MAP kinase inhibitors | MAPK1, MAPK8, MAP3K8 | MAPK14 32/4885FGFR1 1317/4885FGFR2 2815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.